Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: Br J Haematol. 2008 Mar 26;141(4):433–444. doi: 10.1111/j.1365-2141.2008.06982.x

Table II.

Multivariate analysis of clinical outcomes with total therapy 2 (TT2) by protocol arm.

Overall survival Event-free survival CR duration
Cytogenetic abnormalities (CA) 188/634 (30%) 1.95 (1.50, 2.53) <0.001 1.31 (1.11, 1.56) 0.002 83/332 (25%) 1.95 (1.38, 2.77) <0.001
Creatinine ≥176.8 μmol/l 60/634 (9%) 1.57 (1.09, 2.27) 0.017 NS2 NS2 – NS2 NS2
LDH ≥190 U/l 197/634 (31%) 1.47 (1.12, 1.92) 0.005 1.38 (1.17, 1.64) <0.001 – NS2 NS2
Albumin <35 g/l 117/634 (18%) 1.45 (1.07, 1.95) 0.015 NS2 NS2 – NS2 NS2
Randomization to thalidomide 309/634 (49%) NS2 NS2 0.84 (0.72, 0.99) 0.032 – NS2 NS2

Results given as Hazard Ratio (95% confidence intervals), P-value from Wald chi-square test in Cox regression.

NS2 – Multivariate results not statistically significant at 0.05 level.

Multivariate model uses stepwise selection with entry level 0.1 and variable remains if it meets the 0.05 level.

Other variables considered for OS and EFS: age, Hb, CRP, albumin and B2M; for CR duration: creatinine and B2M.